I emailed with an acquaintance who is a doctor and is up to speed on leronlimab and to a lesser degree the CytoDyn story. I asked him if he was going to put an email together to introduce health care professionals to leronlimab, what would be the most eye-catching information. Basically, what are leronlimab's "greatest hits" in the COVID space.

Here's his summary:

Quote:

---

* Safe to use compared to SOC

* Most mild to moderate patients will resolve their symptoms with supportive treatment by day 14. Thus this is the most difficult group to achieve statistical significance.

* But compared to standard of care (SOC), by day 3, leronlimab showed faster clinical improvement, thus shortening hospitalization and saving the healthcare system, hospital and patients $$$. We expect that by day 14 there is no difference between leronlimab and SOC because people get better on their own in this group.

* I would also include Patterson's Montefiore data here too
a. eIND from Montefiore showed
1. normalization of CD4/CD8 ratios
2. decrease of IL-6 and RANTES by day 3
3. decrease in viral loads by day 7 and zero viral load by day 14

So to summarize:
1. Save $$$
2. Safe drug to use
3. Get people out of the hospital quicker before they progress into S/C group
4. restoration of immune system

---

I thought it was pretty a pretty good recap.